Literature DB >> 8162813

[Bassini and Shouldice repair of inguinal hernia. A retrospective comparative study].

H Mückter1, G Reuters, W Vogel.   

Abstract

Between 1987 and 1991 394 primary inguinal hernias in 370 patients were treated in a series of 199 patients using Bassini repair and a consecutive series of 195 patients using Shouldice repair. No intraoperative complications were seen in either group. During hospitalisation time 2 early recurrences were seen after Bassini repair, but there were no significant differences in postoperative haematomas, wound infections and thromboembolic complications between both groups. Recurrence rate was 21.6% in Bassini repair after a mean observation period of 48 months and 2.6% in Shouldice repair after a mean observation period of 26 months. A higher rate of hypesthesia was found after Shouldice repair. There was no incidence of postoperative testicular atrophy, granuloma or hydrocele in both groups. According to the significantly lower recurrence rate and good acceptance by the patients the Shouldice procedure currently seems to be the best standard for inguinal hernia repair.

Entities:  

Mesh:

Year:  1994        PMID: 8162813

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  3 in total

1.  Prosthetic repair of incarcerated inguinal hernias: is it a reliable method?

Authors:  Hayrullah Derici; Haluk R Unalp; Okay Nazli; Erdinc Kamer; Murat Coskun; Tugrul Tansug; Ali D Bozdag
Journal:  Langenbecks Arch Surg       Date:  2008-05-27       Impact factor: 3.445

2.  Herniation after deep circumflex iliac artery flap: two cases of rare complication.

Authors:  Hee-Sung Kim; Jae-Young Kim; Hyuk Hur; Woong Nam
Journal:  Maxillofac Plast Reconstr Surg       Date:  2016-02-25

3.  Short- and long-term outcomes of incarcerated inguinal hernias repaired by Lichtenstein technique.

Authors:  Andrzej Wysocki; Marcin Strzałka; Marcin Migaczewski; Piotr Budzyński
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-04-01       Impact factor: 1.195

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.